Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

Recruiting now · Not applicable

Conditions studied: Acute MI, Heart Failure, Diabetes Mellitus, Kidney Disease

In brief

The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.

Key facts

Study ID

NCT07403669

Run by

Aventyn, Inc.

People needed

300

Starts

2025-10-22

Expected to finish

2027-04-22

Last updated by the study team

2026-02-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women over 18 years of age are included
• Eligible subjects must have one of the risk factor/ disease component of CKM:
• Diabetes with A1C of 7.5 or higher;
• or Heart disease with stent placement;
• or Coronary Artery Bypass Graft (CABG) in the last 12 months;
• or Chronic Kidney Disease (CKD) stage 2- 4
• and, in those with Heart failure, a recent hospitalization within one week of enrollment is required

You may not qualify if…

• Those subjects who are not willing to sign an informed consent

Where it is running

• Gilbert Cardiology — Gilbert, Arizona, United States (enrolling)
• Arizona Heart Foundation — Phoenix, Arizona, United States (enrolling)
• Fountains Family Care — Chandler, Arizona, United States
• East Valley Diabetes — San Tan Valley, Arizona, United States
• Karolinska University Hospital — Stockholm, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.